ask andreas moritz glutathione eBook Andreas Moritz: Bücher, Biographie, neuestes
Description
Tirzepatide, the first dual GIP/GLP-1 receptor agonist (RA), received US Food and Drug Administration (FDA) approval for the treatment of T2DM in May 2022 and for chronic weight management in November 2023 [4]
Food Control 2011;22(10):1653-6
Mar 2018;128(3):763-768
To address this, the problem formulation (2) needs to be extended and transformed into an optimal control problem
